Fate Therapeutics, Inc.

$1.970
USD
Last updated on --.
24h volume3.78M
24h highest2.3340 USD
24h lowest1.9550 USD
24h Price movement-0.51%

FATE recent prices

24 Hours
-0.51%-$0.01
30 days
-17.57%-$0.42
60 days
+66.95%+$0.79
90 days
+48.12%+$0.64

Key data

Previous close1.9800 USD
Market cap331.03M USD
Volume3.78M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-1.1100 USD
Net income (FY)-129.91M USD
Revenue (FY)6.32M USD
Last report dateMay 13, 2026

About Fate Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersSAN DIEGO
Employees (FY)161.00
Revenue per employee (FY)39.23K USD
Net income per employee (FY)-806.88K USD
Listed onNasdaq
Official website

FATE conversion tables

FATEFATE
USDUSD
0.5 FATE0.985 USD
1 FATE1.970 USD
5 FATE9.850 USD
10 FATE19.7 USD
USDUSD
FATEFATE
0.5 USD0.25381 FATE
1 USD0.50761 FATE
5 USD2.538 FATE
10 USD5.076 FATE

FAQ

FATE is trading at $1.970, -0.51% over the last 24 hours. Track live moves on the price chart at the top of this page.
The FATE stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. FATE is currently trading at $1.970, -0.51% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on FATE price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. FATE's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from FATE; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against FATE's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Fate Therapeutics, Inc.'s market cap is currently 331.03M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume3.78M
24h highest2.3340 USD
24h lowest1.9550 USD
24h Price movement-0.51%
FATEFATE
USDUSD
Start trade with FATE Perpetual